Makes guidewires and catheters used in cardiovascular and other minimally invasive medical procedures.
Makes guidewires and catheters used in cardiovascular and other minimally invasive medical procedures.
Sells guidewires and catheters both under its own Asahi brand and as components to larger device makers who sell them under their names, so some sales depend on those partners' volumes. Revenue rests on the number of procedures where a guidewire is used.
In one line: A specialized medical-device maker like a smaller Boston Scientific supplier.
Moat: narrow (process know-how, IP / patents). Precision wire-forming know-how for ultra-thin guidewires is difficult to replicate.
Headquarters: Nagoya, Japan · Founded: 1972 · Employees: 10,177
Size Asahi Intecc (7747.T) is a Japan Health Care company (Medical Specialties) with a market value of $7.09B, the 187th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,225 on 18 Nov 2026.
Performance Over six months the shares gained 24.5%, against +30.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 22.6% over the last twelve months (peer median +5.4%); the operating margin is 32.4% (peer median 15.7%).
Valuation It trades at 29.7× forward earnings against a peer median of 20.9× (5th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.0 points above its cost of capital (8.7% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥153B | ¥145B | ¥120B | ¥108B | ¥90.1B |
| Revenue growth | — | +21% | +12% | +19% | — |
| Gross profit | ¥109B | ¥99.4B | ¥78.2B | ¥66.1B | ¥56.3B |
| EBITDA | ¥58.4B | ¥54.0B | ¥40.2B | ¥31.9B | ¥26.7B |
| Net income | ¥35.6B | ¥32.1B | ¥12.7B | ¥15.8B | ¥13.1B |
| Free cash flow | n/a | ¥31.7B | ¥32.4B | ¥24.8B | ¥6.85B |
| Capital expenditure | n/a | ¥8.93B | ¥8.58B | ¥10.5B | ¥12.7B |
| Total debt | ¥6.04B | ¥9.13B | ¥11.5B | ¥8.59B | ¥16.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Asahi Intecc 7747.T | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Terumo 4543.T | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7747.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.6% | +8.5% | 3rd highest of 21 |
| 6-month return | +24.5% | +30.9% | 8th lowest of 21 |
| Distance from 52-week high | -2.4% | -7.2% | 7th highest of 21 |
| Revenue growth (TTM) | +22.6% | +5.4% | 3rd highest of 21 |
| Operating margin | 32.4% | 15.7% | 3rd highest of 21 |
| Forward P/E | 29.7× | 20.9× | 5th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 15.1% | 10.6% | 6th most demanding of 20 |
| Growth delivered (Del g) | +18.8% | +9.5% | 5th highest of 20 |
| Hurdle (Req g minus delivered) | -3.6 pp | +2.0 pp | 8th least demanding of 20 |
| ROIC minus cost of capital | +18.0 pp | +2.8 pp | 3rd highest of 21 |
| EV / EBITDA | 18.6× | 15.2× | 6th most expensive of 19 |
| Net debt / EBITDA | -0.8× | 0.9× | least indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |